NDAORALTABLET
Approved
Dec 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYSTOLIC (nebivolol hydrochloride) is a selective beta-1 adrenergic receptor antagonist indicated for the treatment of hypertension. It reduces blood pressure by decreasing heart rate and cardiac contractility. The drug is administered orally as a tablet and is used as monotherapy or in combination with other antihypertensive agents.
$24MPart D
LOE ApproachingDeclining
Mature product approaching loss of exclusivity with modest Part D utilization signals contraction; brand defense and cost-containment strategies will dominate team focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BYSTOLIC roles focus on defending market share in a competitive, maturing category rather than driving growth or innovation. Career trajectory on this product emphasizes commercial optimization, managed care negotiation, and cost-containment strategy in the face of generic erosion.
Brand ManagerProduct Manager
Worked on BYSTOLIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.